Risk factor
Fair trading liquidity
Profitability factor
Very weak growth
About
Medicalsystem Biotechnology Co., Ltd. provides clinical diagnostics reagents and instruments in China. The company offers PCR kit, antibody test kit, antigen test kit, and nucleic acid reagent for COVID-19; automated biochemistry analyzers and bio reagents; hematology analyzers; urine analyzers; glycated hemoglobin analyzer; POCT; and chemiluminescene immunoassay analyzers. It also provides healthcare services. The company was formerly known as Ningbo Medicalsystem Biotechnology Co., Ltd. and changed its name to Medicalsystem Biotechnology Co., Ltd. in January 2017. Medicalsystem Biotechnology Co., Ltd. was founded in 2003 and is based in Ningbo, China.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA, overvalue
Buy
Sell